Physician profile
Mohammad A Alsoub
NPI 1063407534
$6,268.98
in general payments reported to CMS, 2019-2025
40 companies · $2,343 in 2025
The $2,343 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $76.65 · 2021: $309 · 2022: $692 · 2023: $812 · 2024: $1,660 · 2025: $2,343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,548 · Education: $266.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,548.41 |
| Education | $266.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $765.19 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $610.98 | 2022-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $498.69 | 2020-2025 | Airsupra, Tezspire, Fasenra |
| Insmed, INC. | $443.11 | 2020-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $427.06 | 2024-2025 | |
| Mylan Specialty L.P. | $416.17 | 2021-2024 | Yupelri |
| Harmony Biosciences LLC | $410.17 | 2021-2025 | Wakix |
| Inspire Medical Systems, INC. | $381.99 | 2023-2025 | Inspire |
| Ethicon INC. | $331.88 | 2024-2025 | Monarch Platform |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.82 | 2021-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Viatris Specialty LLC | $186.56 | 2025 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $175.64 | 2024-2025 | Opsumit, Uptravi |
| Mallinckrodt Hospital Products INC. | $136.11 | 2020-2023 | Acthar |
| Vapotherm INC | $134.08 | 2019-2022 | |
| Baxter Healthcare | $121.57 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $116.78 | 2021-2024 | |
| Electromed, INC. | $108.74 | 2023-2025 | Smartvest |
| Csl Behring | $65.14 | 2019-2021 | |
| Verona Pharma, INC. | $57.55 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Axsome Therapeutics, INC. | $52.67 | 2024-2025 | Sunosi |
| Pfizer INC. | $48.07 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $44.56 | 2022-2023 | Quviviq |
| Philips North America LLC | $42.56 | 2022-2025 | Vest Therapy Und |
| Grifols USA, LLC | $42.24 | 2024 | Prolastin-C Liquid |
| Genentech USA, INC. | $41.93 | 2021-2022 | |
| Lilly USA, LLC | $37.04 | 2025 | Zepbound |
| Medical Device Business Services, INC. | $37.03 | 2025 | Monarch |
| Ani Pharmaceuticals, INC. | $36.59 | 2025 | Purified Cortrophin Gel |
| Vifor Pharma, INC. | $32.87 | 2024 | Zemaira |
| Advanced Respiratory, INC | $26.69 | 2021 | |
| Amgen INC. | $24.25 | 2025 | Tezspire |
| Merck Sharp & Dohme LLC | $20.99 | 2025 | Zerbaxa |
| Abbvie INC. | $16.76 | 2023 | Avycaz |
| Novartis Pharmaceuticals Corporation | $16.35 | 2025 | |
| Lundbeck LLC | $14.95 | 2023 | Rexulti |
| Inogen, INC. | $14.93 | 2023 | Inogen At Home Stationary Concentrator |
| Itamar Medical INC | $13.79 | 2023 | Watchpatone |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Alsoub listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.